Brensocatib

Generic Name
Brensocatib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H24N4O4
CAS Number
1802148-05-5
Unique Ingredient Identifier
25CG88L0BB
Background

Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).

Indication

用于非囊性纤维化支气管扩张症(NCFBE)成人患者的治疗。

Associated Conditions
-
Associated Therapies
-
globenewswire.com
·

Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report

The 'Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024' report highlights emerging therapies like Brensocatib and HSK31858, which aim to address the underlying mechanisms of NCFB, potentially improving patient quality of life. Key industry players are actively developing these therapies, with significant implications for managing NCFB.
globenewswire.com
·

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over

Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.
cnbc.com
·

Caligan takes a stake in Verona Pharma, sees opportunity to generate more value

Verona Pharma, a biopharmaceutical company, focuses on respiratory disease treatments, with ensifentrine in Phase 3 trials for COPD, asthma, and cystic fibrosis. Caligan Partners LP, an activist investor, sees potential in Verona's ensifentrine, predicting significant revenue growth and possible indication expansion for non-cystic fibrosis bronchiectasis.

Insmed's Q3 2024: Strong Growth and Strategic Advances

Insmed (INSM) reported Q3 2024 revenue of $93.4M, up 18% YoY, driven by ARIKAYCE sales growth. The company is on track for Brensocatib's U.S. launch in 2025, with an expanded U.S. sales force and improved financial terms. Insmed remains committed to 2024 ARIKAYCE revenue guidance and pipeline advancements.
investing.com
·

Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch

Insmed reports strong Q3 2024 results, with global net revenues up 18% YoY to $93.4M, driven by ARIKAYCE sales growth. The company plans to file an NDA for brensocatib in Q4 2024, anticipating a mid-2025 launch. Insmed's U.S. sales force has expanded to 184 reps, and cash reserves stand at $1.5B. The company maintains full-year revenue guidance of $340M to $360M and expects peak sales for brensocatib to exceed $5B. Insmed is also advancing clinical trials for brensocatib in chronic rhinosinusitis and hidradenitis suppurativa, with results expected by late 2025.
investing.com
·

Truist Securities raises Insmed stock price target as confidence grows in brensocatib launch

Truist Securities raised Insmed's price target to $100 from $85, retaining a Buy rating, following a survey on brensocatib's market potential. The survey's positive results led to an estimated peak sales increase to $8 billion. Insmed plans to file a New Drug Application for brensocatib in Q4 2024, with a mid-2025 launch anticipated. InvestingPro data supports Insmed's strong revenue growth and financial stability.
prnewswire.com
·

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients

Insmed presented positive subgroup data from the Phase 3 ASPEN study on brensocatib for non-cystic fibrosis bronchiectasis at CHEST 2024, showing consistent efficacy across subgroups. Brensocatib demonstrated reduced lung function decline and was well-tolerated. Insmed plans to file a New Drug Application for brensocatib in Q4 2024, aiming for a U.S. launch in mid-2025 and European/Japanese launches in early 2026.

Risk Adjusted Net Present Value: What is the current valuation of Insmed's Treprostinil Palmitil

Treprostinil Palmitil, a drug under development for rare pulmonary disorders, is expected to generate $334 mn in annual revenue by 2037 in the US. Insmed, the biopharmaceutical company developing it, reported a net loss of $749.6 mn in FY2023. The drug's risk-adjusted NPV model (rNPV) considers the risk of failure in clinical development.
© Copyright 2024. All Rights Reserved by MedPath